Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Blood (2019) 134 (Supplement_1): 754.

https://doi.org/10.1182/blood-2019-126064

Published: 2019

Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 4013.

https://doi.org/10.1182/blood-2018-99-115486

Published: 2018

Journal Articles

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

Carter Thomas Davis, MD, Arati V. Rao, MD, Eross Guadalupe, Dale J. Christensen, PhD, J. Brice Weinberg, MD

Blood (2016) 128 (22): 5126.

https://doi.org/10.1182/blood.V128.22.5126.5126

Published: 2016

Journal Articles

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Cristina Gasparetto, MD, Michael Green, MD, Anandgopal Srinivasan, MDcal Student, Yubin Kang, MD, David A. Rizzieri, MD, Carlos Decastro, MD, Louis F. Diehl, MD, Anne Beaven, MD, Zighuo Li, PhD, Arati V. Rao, MD, Anderson Garrett, Sascha Tuchman, MD, Gwynn D. Long, MD

Blood (2015) 126 (23): 1857.

https://doi.org/10.1182/blood.V126.23.1857.1857

Published: 2015

Journal Articles

Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Eunice S. Wang, MD, Gary J Schiller, MD, Leonard T. Heffner, MD, Wendy Stock, MD, Arati V. Rao, MD, Gail J. Roboz, MD, Peter Westervelt, MD PhD, Matthew J. Wieduwilt, MD PhD, Jay Yang, MD, Lucy Prasad, Karen Segarini, Stuart L. Goldberg, MD

Blood (2015) 126 (23): 2491.

https://doi.org/10.1182/blood.V126.23.2491.2491

Published: 2015

Journal Articles

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2536.

https://doi.org/10.1182/blood.V126.23.2536.2536

Published: 2015

Journal Articles

Acute and Chronic Lymphocytic Leukemia Induces Exhaustion and Suppresses Metabolic Reprogramming in T Cell Activation

Peter J. Siska, MD, J. Brice Weinberg, MD, Arati V. Rao, MD, James R. Bain, PhD, Michael J. Muehlbauer, PhD, Tingyu Liu, Jeffrey Rathmell, PhD

Blood (2014) 124 (21): 4121.

https://doi.org/10.1182/blood.V124.21.4121.4121

Published: 2014

Journal Articles

Exome Sequencing Reveals The Genetic Landscape Of Rare Atypical e6a2 CML

Arati V. Rao, MD, Yuri D. Fedoriw, MD, Kristy L. Richards, MD PhD, Zhen Sun, MS, Cassandra L Love, MS, Sandeep Dave, MD

Blood (2013) 122 (21): 3995.

https://doi.org/10.1182/blood.V122.21.3995.3995

Published: 2013

Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Blood (2013) 122 (21): 1548.

https://doi.org/10.1182/blood.V122.21.1548.1548

Published: 2013

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Carlos Manuel de Castro, III, MD, Donna Adams, RN, Arati V Rao, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Julie Warzecho, RN, David A. Rizzieri, MD

Blood (2011) 118 (21): 5029.

https://doi.org/10.1182/blood.V118.21.5029.5029

Published: 2011

Journal Articles

Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.

Arati V. Rao, MD, David A. Rizzieri, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Louis F. Diehl, MD, Amy P. Abernethy, MD, PhD, McLean Jordan, RN, Patty Davis, RN, Emily Edmonds, RN, Jon P. Gockerman, MD

Blood (2005) 106 (11): 4610.

https://doi.org/10.1182/blood.V106.11.4610.4610

Published: 2005

NARROW

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Acute and Chronic Lymphocytic Leukemia Induces Exhaustion and Suppresses Metabolic Reprogramming in T Cell Activation

Exome Sequencing Reveals The Genetic Landscape Of Rare Atypical e6a2 CML

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only